Barbara Lopez Kunz

In her role as CEO, Barbara Lopez Kunz brings a blend of industry knowledge, global business acumen, and people-centered leadership to Caidya. Having served on Caidya’s board of directors since 2022, Barbara has been instrumental in strategy and corporate governance.

During her more than 30-year career, Barbara has held executive roles in a number of prominent organizations. As the President & CEO of the Drug Information Association (DIA), she led the organization through a digital transformation and organizational turnaround resulting in active engagement by regulatory authorities around the globe. As President of Battelle’s global health and life sciences business, she drove the growth of both corporate and public sector work in clinical research, medical devices and diagnostics, and in public health. As EVP at Thermo Fisher Scientific, she oversaw the evolving biosciences portfolio resulting from a focused M&A strategy. She also has held leadership roles at DuPont and ICI, starting out as a research scientist.

Outside of Caidya, Barbara serves as a director on the board of Werfen, a leader in specialized diagnostics. She also is a director at Aptevo Therapeutics (NASDAQ: APVO) and serves as vice-chair of the board of Children’s National Hospital.

Barbara holds an MSc in Polymer Science from the University of Akron and completed the International Executive Program at INSEAD. Her industry contributions are recognized through her Fellowships with DIA and Certification with the National Association of Corporate Directors. Overall, Barbara Lopez Kunz’s career is distinguished by her strategic foresight, leadership excellence, and a dedication to advancing the life sciences field.